A new study shows that in patients with intermediate nonneovascular age-related macular degeneration, levodopa treatment is ...

A McGill-led study is challenging a popular theory about how dopamine drives movement, a discovery that could shift how ...

A McGill-led study is challenging a popular theory about how dopamine drives movement, a discovery that could shift how ...

Explore dopamine's role in movement and how it challenges long-standing theories about motor control and Parkinson's disease ...

Wilmington, New Castle, Delaware, April 23, 2024 (GLOBE NEWSWIRE) -- Allied Market Research has recently published a report, titled, “Levodopa Market Size, Share, Competitive Landscape and Trend ...

Please provide your email address to receive an email when new articles are posted on . Apomorphine sublingual film resulted in greater motor improvement and an increase in responders at earlier time ...

The FDA approved an oral extended-release formulation of levodopa and carbidopa known as IPX203 (Crexont) to treat Parkinson's disease, Amneal Pharmaceuticals announced Wednesday. The treatment is a ...

Treatment with Crexont statistically significantly improved “On” time without troublesome dyskinesia compared with carbidopa/levodopa IR. The Food and Drug Administration (FDA) has approved Crexont ® ...

A type of supplement known as the "dopamine bean" can contain very high levels of levodopa -- in some cases, higher than prescription formulations used to treat Parkinson's disease, researchers found.

Report in the Journal of Parkinson's Disease presents data from one-year trial on long-term safety, efficacy, and quality of life in advanced PD patients using levodopa-carbidopa intestinal gel ...